A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Tisotumab-vedotin (Primary) ; Gemcitabine; Irinotecan; Pemetrexed; Topotecan; Vinorelbine
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms innovaTV 301
- Sponsors Pfizer; Seagen
- 17 Jun 2024 Planned End Date changed from 28 Feb 2028 to 5 Aug 2025.
- 17 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology